Sign In
Last checked at 
8 Jan 2018 07:00
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Directorate changes
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announces that further to the announcement dated 5 December 2017, Richard Colin Neil Davidson CBE has been appointed as Non-Executive Chairman to the Company. Simultaneous with Mr Davidson's appointment, Adam Reynolds, as previously disclosed, has stepped down as a director of the Company.
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Richard Colin Neil Davidson CBE (aged 66):
Current Appointments | Appointments in the last 5 years |
Bridge4 Health Limited | Competition Law Process Management Limited |
Bridge4 Rehabilitation Limited | Eminate Limited |
Cricketarchive Limited | Maplewell Limited |
Eclipse Film Partners No.38 LLP | Persimmon Plc |
Foodzeen Limited | Produce Investments Plc |
T S Bloor & Sons Limited | Television Nottingham Limited |
Testmatchextra.com Limited |
|
The Cricketer Publishing Limited |
|
Thixate Limited |
|
United Church Schools Foundation Limited |
|
United Learning Trust |
|
WM Morrison Supermarkets Plc |
|
Wireframe IO Limited |
|
There is no information regarding Mr Davidson required to be disclosed under the AIM Rules.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc | www.optibiotix.com | |
Stephen O'Hara, Chief Executive | Contact via Walbrook below | |
|
| |
Cairn Financial Advisers LLP | Tel: 020 7213 0880 | |
Liam Murray / Jo Turner |
| |
|
| |
finnCap Broker | Tel: 020 7220 0500 | |
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance) |
| |
Tony Quirke (Corporate Broking) |
| |
|
| |
Walbrook PR Ltd | Tel: 020 7933 8780 or optibiotix@walbrookpr.com | |
Anna Dunphy | Mob: 07876 741 001 | |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.
Follow the stocks
